SOLIDEX®-ISOEx TCR alpha-beta (abT)+ Cell Isolation Solution
Introduction of SOLIDEX®-ISOEx TCR alpha-beta (abT)+ Cell Isolation Solution
TCRαβ+ Cells refer primarily to T cells that express αβ T cell receptors (TCR), including CD4+ helper T cells and CD8+ cytotoxic T cells. These cells make up more than 95% of the peripheral blood T cells and are a core component of the adaptive immune system.
TCRαβ is a heterodimer receptor on the surface of T cells, composed of α and β chains, specifically expressed on conventional T cells but not on γδ T cells or non-T cells, providing highly specific antigen recognition. GeneMedi offers TCR alpha-beta (abT)+ cell magnetic beads for the positive selection or depletion of TCRαβ+ cells to meet various research and therapeutic needs.
Isolation method of SOLIDEX®-ISOEx TCR alpha-beta (abT)+ Cell Isolation Solution
- Positive Selection
- Depletion
Research Applications:
Positive selection is used to isolate TCRαβ+ T cells, allowing further analysis of white blood cell concentration, cell viability, and immune cell composition (including B cells). This process helps deepen the understanding of the roles and interactions of different immune cell populations in the immune system.
| Cat.No | Product Name | Products Information |
|---|---|---|
| GM-Tg-hg-MP2610-iso-nanoIMB | SOLIDEX®-ISOEx Human TCR alpha-beta (abT) Isolation Nanobeads (Column-based) | Details |
| GM-Tg-hg-MP2610-iso-nanoIMB-CF | SOLIDEX®-ISOEx Human TCR alpha-beta (abT) Isolation Nanobeads (Column-free) | Details |
| GM-Tg-hg-MP2610-iso-rel-kit | SOLIDEX®-ISOEx Indirect Releasable Human TCR alpha-beta (abT)+ Cell Isolation Kit (Column-based) | Details |
| GM-Tg-hg-MP2610-iso-rel-kit-CF | SOLIDEX®-ISOEx Indirect Releasable Human TCR alpha-beta (abT)+ Cell Isolation Kit (Column-free) | Details |
| GM-Tg-hg-MP2610-iso-kit | SOLIDEX®-ISOEx Indirect Human TCR alpha-beta (abT)+ Cell Isolation Kit (Column-based) | Details |
| GM-Tg-hg-MP2610-iso-kit-CF | SOLIDEX®-ISOEx Indirect Human TCR alpha-beta (abT)+ Cell Isolation Kit (Column-free) | Details |
Clinical Applications:
In hematopoietic stem cell transplantation (HSCT), studies show that removing αβ T lymphocytes from peripheral blood stem cells (PBSC), while retaining all other cell populations, supports allogeneic transplantation by providing immune modulation and reducing transplant rejection responses. Additionally, TCRαβ/CD19 depletion in hematopoietic stem cell transplantation has shown promising applications in treating hematologic malignancies. Finally, a clinical trial studied the effect of TCRαβ+ and CD19+ cell depletion on enhancing γδ T cell cytotoxicity against leukemia cells in the presence of ZOLE (Zoledronic acid), with results showing that T cell reconstitution played a positive regulatory role during treatment.
| Cat.No | Product Name | Products Information |
|---|---|---|
| GM-Tg-hg-MP2610-dep-nanoIMB | SOLIDEX®-ISOEx Human TCR alpha-beta (abT)+ Cell Depletion Nanobeads (Column-based) | Details |
| GM-Tg-hg-MP2610-dep-kit | SOLIDEX®-ISOEx Indirect Human TCR alpha-beta (abT)+ Cell Depletion Kit (Column-based) | Details |
Validation Data
Efficient depletion of TCR alpha-beta (αβ)+ T cells from human PBMC using the SOLIDEX®-ISOEx Indirect Human TCR alpha-beta (αβ)+ Cell Depletion Kit (Column-based)
Catalog No. GM-Tg-hg-MP2610-dep-kit
This experiment was designed to evaluate the depletion efficiency of the SOLIDEX®-ISOEx Indirect Human TCR alpha-beta (αβ)+ Cell Depletion Kit (Column-based) for removing TCR alpha-beta (αβ)+ cells. Data analysis demonstrated the kit's excellent depletion performance. In the initial PBMC sample, TCR alpha-beta (αβ)+ cells accounted for 54.7%. After processing through the separation column, the residual TCR alpha-beta (αβ)+ cells in the flow-through fraction dramatically decreased to 0.079%, indicating a depletion efficiency exceeding 99.3%. These results confirm that the kit achieves highly efficient depletion with excellent specificity, without causing non-specific loss of non-target cells.
Figure 11. Efficient depletion of TCR alpha-beta (αβ)+ cells from human PBMC using the SOLIDEX®-ISOEx Indirect Human TCR alpha-beta (αβ)+ Cell Depletion Kit (Column-based). Results show that the proportion of TCR alpha-beta (αβ)+ cells was 54.7% before depletion (Pre-depletion) and decreased to 0.079% after depletion (After Depletion / Flow-through). This demonstrates that up to 99.3% of TCR alpha-beta (αβ)+ cells were captured and retained by the magnetic separation column, confirming the high specificity of bead capture for TCR alpha-beta (αβ)+ cells.
